Shares of the distressed insulin maker Mannkind (MNKD) plummeted nearly 16% Thursday morning following a conference call with investors and analysts. Proposed changes to its Afrezza drug and its sales structure may not produce the results the drugmaker seeks.
More from Video
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.
Citi overcame a mixed print to send its stock surging on Monday.